Exhibit
10.1


 


JOSEPH
GUNNAR & CO., LLC


30
Broad Street, 11th Floor

New York, NY 10004


 


November
29, 2022


 


Theralink
Technologies, Inc.

15000 W. 6th Ave., #400


Golden,
CO 80401

Attn: Mick Ruxin, M.D.


 


Dear
Mr. Ruxin:


 


This
Placement Agency Agreement will confirm our agreement that Theralink Technologies, Inc. (the “Company”) has engaged
Joseph Gunnar & Co., LLC (“Gunnar” or “Placement Agent”) to act as its exclusive placement
agent with respect effectuating an offering of its securities for the offering period described below (the “Term”).
For purposes of this agreement, the term “Offering” means a private placement pursuant to which the Company will be
offering a minimum of $2,750,000 in principal amount (“Minimum Amount”) and up to a maximum of $6,600,000 in principal
amount (“Maximum Amount”) of Debentures and Warrants; provided, however, that upon the written consent of the Company
and the Placement Agent, the Maximum Amount shall be adjusted upward to an aggregate of $8,000,000 in principal amount of Debentures.
Based on the 10.0% Original Issue Discount on the Debentures, gross proceeds in cash payments from investors shall be $2,500,000 on the
Minimum Amount and $6,000,000 on the Maximum Amount or $7,200,000 if increased as provided above. Placement of the Debentures and Warrants
will be made on a “commercially reasonable efforts, all or none” basis as to the Minimum Amount and on a “commercially
reasonable efforts basis for all amounts in excess of the Minimum Amount. All capitalized terms used herein that are not otherwise defined
herein shall have the meaning ascribed to such terms in the Purchase Agreement (as defined below).


 


The
Placement Agent shall offer the Debentures and Warrants only to persons or entities who qualify as “accredited investors,”
as such term is defined in Rule 501 of Regulation D (“Regulation D”) as promulgated by the United States Securities
and Exchange Commission (the “SEC”) under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”).
The Debentures and Warrants will be offered until the earlier of (i) the termination of the Offering as provided herein, (ii) the time
that all Debentures and Warrants offered in the Offering are sold, or (iii) December 31, 2022 (“Initial Offering Period”),
which date may be extended by the Placement Agent and the Company in their joint discretion until January 31, 2023 (this additional
period and the Initial Offering Period shall be referred to as the “Offering Period”). The date on which the Offering
expires or is terminated shall be referred to as the “Termination Date.”


 


The
offering of the Debentures and Warrants will be made solely pursuant to the Disclosure Materials, which at all times will be in form
and substance reasonably acceptable to the Placement Agent and the Company and their respective counsels and contain such legends and
other information as the Placement Agent, the Company and their counsels may, from time to time, deem necessary and desirable to be set
forth therein. “Disclosure Materials” as used in this Agreement means that certain Securities Purchase Agreement pursuant
to which the Debentures and Warrants are to be sold, inclusive of all exhibits and all amendments, supplements and appendices thereto
(the “Purchase Agreement”). Unless otherwise defined, each term used in this Agreement will have the same meaning
as set forth in the Disclosure Materials.


 






    	 



    	Theralink Technologies, Inc.
	November 29, 2022



    

 


1.
Representations and Warranties of the Company. Except as set forth in the Disclosure Materials, the representations and warranties of
the Company contained below are true and correct as of the date of this Agreement:


 


(a)
The Disclosure Materials haves been diligently prepared by the Company, in conformity with all applicable laws and the requirements of
all other rules and regulations of the Securities and Exchange Commission (the “SEC”) relating to offerings of the
type contemplated by the Offering, and the applicable securities laws and the rules and regulations of those jurisdictions wherein the
Debentures and Warrants are to be offered and sold. With respect to actions taken by the Company, the Debentures and Warrants will be
offered and sold pursuant to the registration exemption provided by Rule 506(b) of Regulation D and Section 4(a)(2) of the Securities
Act as a transaction not involving a public offering and the requirements of any other applicable state securities laws and the respective
rules and regulations thereunder in those jurisdictions in which the Placement Agent notifies the Company that the Debentures and Warrants
are being offered for sale. The Company has not taken nor will it take any action which conflicts with the conditions and requirements
of, or which would make unavailable with respect to the Offering, the exemption(s) from registration available pursuant to Regulation
D or Section 4(a)(2) of the Securities Act, and knows of no reason why any such exemption would be otherwise unavailable to it. The Company
has not been subject to any order, judgment or decree of any court of competent jurisdiction temporarily, preliminarily or permanently
enjoining it for failing to comply with Section 503 of Regulation D.


 


(b)
The Disclosure Materials do not include any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; provided,
however, the foregoing does not apply to any statements or omissions made solely in reliance on and in conformity with written
information furnished to the Company by the Placement Agent specifically for use in the preparation thereof. To the Company’s knowledge,
none of the statements, documents, certificates or other items made, prepared or supplied by the Company with respect to the transactions
contemplated hereby contains an untrue statement of a material fact or omits to state a material fact necessary to make the statements
contained therein not misleading in light of the circumstances in which they were made. There is no fact which the Company has not disclosed
in the Disclosure Materials and of which the Company is aware that has had or that could reasonably be expected to have a Material Adverse
Effect. For purposes hereof, “Material Adverse Effect” means any event, circumstance, change or effect that, individually
or in the aggregate with all other events, circumstances, changes and effects, is or is reasonably likely to be materially adverse to
(i) the operations, assets, business, prospects or condition (financial or otherwise) of the Company and its subsidiaries, taken as a
whole or (ii) the ability of the Company to consummate the transactions contemplated by this Agreement and to perform its obligations
under this Agreement, the Debentures and the Warrants.


 






    	2



    	Theralink Technologies, Inc.
	November
                                            29, 2022




    

 


(c)
Except for the compensation set forth in this Agreement, or as set forth on Schedule 3.1(t) to the Purchase Agreement, the Company is
not obligated to pay, and has not obligated the Placement Agent to pay, a finder’s or origination fee in connection with the Offering,
and hereby agrees to indemnify the Placement Agent from any such claim made by any other person as more fully set forth in Section 8
hereof.


 


(d)
The Company has all requisite corporate power and authority to (i) enter into and perform its obligations under this Agreement and (ii)
issue, sell and deliver the Placement Agent Warrants (as hereinafter defined). This Agreement has been duly authorized, executed and
delivered and constitutes valid and binding obligations of the Company, enforceable against the Company in accordance with its terms
(i) except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws now
or hereafter in effect related to laws affecting creditors’ rights generally, including the effect of statutory and other laws
regarding fraudulent conveyances and preferential transfers, and except that no representation is made herein regarding the enforceability
of the Company’s obligations to provide indemnification and contribution remedies under the securities laws and (ii) subject to
the limitations imposed by general equitable principles (regardless of whether such enforceability is considered in a proceeding at law
or in equity).


 


(e)
The Company, as well as all Company Related Persons (as defined below) are not subject to any of the disqualifications set forth in Rule
506(d) of Regulation D (each a “Disqualification Event”). The Company has exercised reasonable care to determine whether
any Company Related Person is subject to a Disqualification Event. The Disclosure Materials contain a true and complete description of
the matters required to be disclosed with respect to the Company and the Company Related Persons pursuant to the disclosure requirements
of Rule 506(e) of Regulation D, to the extent applicable. As used herein, “Company Related Persons” means any predecessor
of the Company, any affiliated Company, any director, executive officer, other officer of the Company participating in the Offering,
any general partner or managing member of the Company, any beneficial owner of 20% or more of the Company’s outstanding voting
equity securities, calculated on the basis of voting power, and any “promoter” (as defined in Rule 405 under the Act) connected
with the Company in any capacity. The Company agrees to promptly notify the Placement Agent in writing of (i) any Disqualification Event
relating to any Company Related Person and (ii) any event that would, with the passage of time, become a Disqualification Event relating
to any Company Related Person.


 


(f)
For the benefit of the Placement Agent, the Company, hereby incorporates by reference all of the representations and warranties as set
forth in Section 3.1 of the Purchase Agreement with the same force and effect as if specifically set forth herein.


 


2.
Representations, Warranties and Covenants of Placement Agent. The Placement Agent represents and warrants to the Company that
the following representations and warranties are true and correct as of the date of this Agreement:


 


(a)
The Placement Agent is a member in good standing of FINRA and is registered as a broker-dealer under the Exchange Act, and under the
securities acts of each state into which it is making offers or sales of the Debentures and Warrants.


 






    	3



    	Theralink Technologies, Inc.
	November
                                            29, 2022




    

 


(b)
Neither Placement Agent nor any Placement Agent Related Persons (as defined below) are subject to any Disqualification Event. Placement
Agent has exercised reasonable care to determine whether any Placement Agent Related Person is subject to a Disqualification Event. As
used herein, “Placement Agent Related Persons” means any director, general partner, managing member, executive officer,
or other officer of Placement Agent participating in the Offering. Placement Agent agrees to promptly notify the Company in writing of
(i) any Disqualification Event relating to any Placement Agent Related Person, and (ii) any event that would, with the passage of time,
become a Disqualification Event relating to any Placement Agent Related Person.


 


3.
Further Covenants. The Company hereby covenants and agrees that:


 


(a)
Except upon prior written notice to the Placement Agent, the Company shall not, at any time prior to the Final Closing (as defined below),
knowingly take any action which would cause any of the representations and warranties made by it in this Agreement not to be complete
and correct in all material respects on and as of each closing date with the same force and effect as if such representations and warranties
had been made on and as of each such date (except to the extent any representation or warranty relates to an earlier date).


 


(b)
If, at any time prior to the Final Closing, any event shall occur that causes a Material Adverse Effect, which as a result it becomes
necessary to amend or supplement the Disclosure Materials so that the representations and warranties herein remain true and correct in
all material respects, or in case it shall be necessary to amend or supplement the Disclosure Materials to comply with Regulation D or
any other applicable securities laws or regulations, the Company will promptly notify the Placement Agent and shall, at its sole cost,
prepare and furnish to the Placement Agent copies of appropriate amendments and/or supplements in such quantities as the Placement Agent
may reasonably request for delivery by the Placement Agent to potential subscribers. The Company will not at any time before the Final
Closing prepare or use any amendment or supplement to the Disclosure Materials of which the Placement Agent will not previously have
been advised and furnished with a copy, or which is not in compliance in all material respects with the Act and other applicable securities
laws. As soon as the Company is advised thereof, the Company will advise the Placement Agent and its counsel, and confirm the advice
in writing, of any order preventing or suspending the use of the Disclosure Materials, or the suspension of any exemption for such qualification
or registration thereof for offering in any jurisdiction, or of the institution or threatened institution of any proceedings for any
of such purposes, and the Company will use its reasonable best efforts to prevent the issuance of any such order and, if issued, to obtain
as soon as reasonably possible the lifting thereof.


 


(c)
The Company shall comply with the Act, the Securities Exchange Act of 1934 (the “Exchange Act”) and the rules and
regulations thereunder, all applicable state securities laws and the rules and regulations thereunder in the states in which the Company’s
Blue Sky counsel has advised the Placement Agent and the Company that the Debentures and Warrants are qualified or registered for sale
or exempt from such qualification or registration, so as to permit the continuance of the sales of the Debentures and Warrants, and will
file or cause to be filed with the SEC, and shall promptly thereafter forward or cause to be forwarded to the Placement Agent, any and
all reports on Form D as are required.


 






    	4



    	Theralink Technologies, Inc.
	November
                                            29, 2022




    

 


(d)
The Company shall use its best efforts to qualify the Debentures and Warrants for sale under the securities laws of such jurisdictions
in the United States as may be mutually agreed to by the Company and the Placement Agent, and the Company will make or cause to be made
such applications and furnish information as may be required for such purposes, provided that the Company will not be required to qualify
as a foreign corporation in any jurisdiction or execute a general consent to service of process.


 


(e)
The Company shall not use any of the net proceeds of the Offering to repay indebtedness or to pay accrued and unpaid salary or bonuses
to officers, directors, employees or any of their respective affiliates or to stockholders of the Company without the prior written consent
of the Placement Agent; provided that the Company may pay up to $300,000 in compensation that is due primarily to certain key members
of the Company’s research and development team, as set forth in the Purchase Agreement.


 


(f)
Except upon obtaining the prior written consent of the Placement Agent, which consent shall not be unreasonably withheld, the Company
shall not, at any time prior to the earlier of the Final Closing or the Termination Date, except as contemplated by the Disclosure Materials
(i) engage in or commit to engage in any transaction outside of the ordinary course of business, (ii) issue, agree to issue or set aside
for issuance any securities (debt or equity) or any rights to acquire any such securities; provided that (a) the Company shall be permitted
to issue stock options, restricted stock and/or restricted stock units, including such as are convertible into, or exercisable for, shares
of Common Stock to officers, directors and employees of the Company in the ordinary course or as permitted by the Purchase Agreement,
(iii) incur, outside the ordinary course of business, any material indebtedness, (iv) dispose of any material assets, or (v) change its
business or operations.


 


(g)
The Company shall pay all of its own expenses for accounting fees, legal fees and other costs involved with the Offering, including without
limitation, expenses incurred in connection with the preparation and printing of all Disclosure Materials and the issuance of the Debentures,
Warrants and the Placement Agent Warrants (as defined below). The Company will provide at its own expense such quantities of the Disclosure
Materials and other documents and instruments relating to the Offering as the Placement Agent may reasonably request. All Blue Sky filings
related to this Offering shall be prepared by the Company’s counsel, at the Company’s expense, with copies of all filings
to be promptly forwarded to the Placement Agent.


 


(h)
Until the earlier of (i) the Termination Date, and (ii) the Final Closing of the Offering, the Company will not issue any press release
except in the ordinary course of business consistent with past practices, grant any interview, or otherwise communicate with the media
in any manner whatsoever with respect to the Offering without the Placement Agent’s prior consent.


 


4.
Escrow of Funds. All funds for subscriptions received by the Placement Agent from the Offering (not otherwise wired directly to
the Escrow Agent), if any, will be promptly forwarded by the Placement Agent and deposited into a non-interest bearing escrow account
(the “Escrow Account”) established for such purpose with Signature Bank (the “Escrow Agent”). All
such funds for subscriptions will be held in the Escrow Account pursuant to the terms of an escrow agreement among the Company, the Placement
Agent and the Escrow Agent (the “Escrow Agreement”). The Company will pay all fees related to the establishment and
maintenance of the Escrow Account. The Company will either accept or reject, for any or no reason, the documents to be returned by investors
as set forth in the Disclosure Materials (the “Subscription Documents”) in a timely fashion and at each Closing, the
Company will countersign the Subscription Documents and provide duplicate copies of such documents to the Placement Agent for distribution
to the subscribers. The Placement Agent on the Company’s behalf, will promptly return to subscribers incomplete, improperly completed,
improperly executed and rejected subscriptions. If Subscription Documents and good available funds for at least the Minimum Amount have
not been received and accepted by the Company on or before the Termination Date for any reason, the Offering will be terminated, no Debentures
and Warrants will be sold, and the Escrow Agent will, at the request of the Placement Agent, cause all monies received from subscribers
for the Debentures and Warrants to be promptly returned to such subscribers without interest, penalty, expense or deduction.


 






    	5



    	Theralink Technologies, Inc.
	November
                                            29, 2022




    

 


If
subscriptions for gross proceeds in cash payment for at least the Minimum Amount have been accepted prior to the Termination Date, the
funds therefor have been collected by the Escrow Agent and all of the conditions set forth elsewhere in this Agreement are fulfilled,
the first closing of the Offering (“First Closing”) shall be held promptly with respect to Debentures and Warrants
sold. Thereafter additional Debentures and Warrants will continue to be offered and sold until the Termination Date and additional closings
(each a “Closing”) may from time to time be conducted at times mutually agreed to by the Placement Agent and the Company
with respect to additional Debentures and Warrants sold, with the final closing (“Final Closing”) to occur within
five (5) business days after the earlier of the Termination Date and the date on which Debentures and Warrants for up to the Maximum
Amount have been fully subscribed for. Delivery of payment for the accepted subscriptions for Debentures and Warrants from funds held
in the Escrow Account will be made at each Closing against delivery of the Debentures and Warrants by the Company. The Company shall
deliver the original securities comprising the Debentures and Warrants per instructions to be provided by Placement Agent within five
(5) business days following each Closing.


 


5.
Compensation to Placement Agent.


 


(a)
In connection with the Offering, the Company will pay Gunnar a cash fee (the “Placement Agent’s Cash Fee”) equal
to 10% of the aggregate gross proceeds raised in the Offering; provided, for the avoidance of doubt, that the Placement Agent’s
Cash Fee shall not take into account that certain capital raise of $1,000,000 invested into the Offering by Jeffrey Busch and Doug Mergenthaler
in exchange for demand notes that were issued prior to the First Closing. As additional compensation, the Company shall issue to the
Placement Agent or its designees at or promptly following the Final Closing of the Offering, five-year warrants, (the “Placement
Agent Warrants”) to purchase 10% of the shares underlying the Debentures issued in the Offering and for these purposes, to
be calculated by the lower of (i) $0.003 per share or (ii) 70% of the 10 day VWAP of the Company’s Common Stock (the “Discounted
VWAP”) immediately preceding the date of the First Closing), at an initial exercise price equal to the Discounted VWAP. For
example, assuming the Maximum Amount is sold and a Discounted VWAP of $0.003 per share, Investors invest $6,600,000 in cash into the
Company. In such event, the Company will issue Placement Agent Warrants to the Placement Agent (and its designees) to purchase 220,000,000
shares of the Company’s common stock at an exercise price of $0.003 per share. In the event of a Dilutive Issuance (as defined
in the Warrants issued in the Offering), the exercise price then in effect for the Placement Agent Warrants shall be reduced to an amount
equal to the New Issuance Price (as defined in the Warrants issued in the Offering) in the same manner as the Warrants issued in the
Offering; provided, however, that the foregoing adjustment shall only be in effect one time only. The Placement Agent Warrants shall
also have cashless exercise provisions and such other terms mutually agreed upon by the Company and the Placement Agent. At each Closing,
the Company will reimburse the Placement Agent for all reasonable, documented marketing, travel and other out-of-pocket expenses incurred
in connection with the Offering up to an aggregate from all Closings of $25,000, plus expense reimbursement of $50,000 to Placement Agent’s
counsel for documented legal expense. In addition, the Company shall pay a non-refundable $50,000 corporate finance advisory fee for
strategic advice and restructuring support to the Placement Agent upon the First Closing.


 






    	6



    	Theralink Technologies, Inc.
	November
                                            29, 2022




    

 


(b)
The Company shall also pay to the Placement Agent the Placement Agent’s Cash Fee to the extent any party first introduced to the
Company by Gunnar via phone call, email, face to face or electronic meeting or transmission of Offering materials (such transmissions
only being made upon authorization from the Company in writing) invests in the Company (other than through open or public market purchases
or securities purchased in any underwritten public offering) at any time prior to the date that is twelve (12) months after the applicable
termination date of the Offering or the Final Closing (“Tail Period”), whichever is applicable. Notwithstanding the
foregoing, this paragraph shall not apply to the extent that the Placement Agent is acting as the placement agent or underwriter or acting
in a similar capacity in connection with such follow-on investment and is already being compensated by the Company pursuant to a separate
engagement. The names of Tail Investors shall be provided in writing by the Placement Agent to the Company upon written request following
the termination date or the Final Closing, as the case may be (the “Tail Investor List”). The Company acknowledges
and agrees that the Tail Investor List is proprietary to the Placement Agent, shall be maintained in strict confidence by the Company
and those persons/entities on such list shall not be contacted by the Company without the Placement Agent’s prior written consent;
provided, however, that such restrictions shall not apply to ordinary course stockholder communications by the Company to its stockholders.


 


6.
Conditions of Placement Agent’s Obligations. The obligations of the Placement Agent hereunder to effect a Closing are subject
to the fulfillment, at or before each Closing, of the following additional conditions:


 


(a)
Each of the representations and warranties made by the Company herein shall be true and correct at all times prior to and on each Closing
date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation
or warranty shall be true and correct as of such earlier date.


 


(b)
The Company shall have performed and complied in all material respects with all agreements, covenants and conditions required to be performed
and complied with by them at or before the Closing.


 


(c)
The Disclosure Materials did not, and as of the date of any amendment or supplement thereto will not, include any untrue statement of
a material fact or omit to state any material fact necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading.


 






    	7



    	Theralink Technologies, Inc.
	November
                                            29, 2022




    

 


(d)
The Company shall have obtained all consents, waivers and approvals required to be obtained by the Company in connection with the consummation
of the transactions contemplated hereby.


 


(e)
No order suspending the use of the Disclosure Materials or enjoining the Offering shall have been issued, and no proceedings for that
purpose or a similar purpose shall have been initiated or pending, or, to the Company’s knowledge, threatened.


 


(f)
The Placement Agent shall have received a certificate of the Chief Executive Officer of the Company, dated as of the date of the Closing,
certifying, as to the fulfillment of the conditions set forth in subparagraphs (a), (b), (c), (d) and (e) above.


 


(g)
The Company shall have delivered to the Placement Agent: (i) a certified charter document and good standing certificate, each dated as
of a date within ten (10) days prior to the First Closing from the secretary of state of its jurisdiction of incorporation; and (ii)
resolutions of the Company’s Board of Directors approving this Agreement and the transactions and agreements contemplated by this
Agreement and the Disclosure Materials, certified by the Chief Executive Officer of the Company.


 


(h)
The Chief Executive Officer of the Company shall have provided a certificate to the Placement Agent confirming that, to the best of his
knowledge, there have been no material adverse changes in the condition (financial or otherwise) or prospects of the Company from the
date of the financial statements included in the Disclosure Materials, the absence of undisclosed liabilities and such other matters
relating to the financial condition and prospects of the Company that the Placement Agent may reasonably request.


 


(i)
At each Closing, the Company shall pay and/or issue to the Placement Agent the Placement Agent Cash Fee and Placement Agent expense reimbursement
earned at such Closing. Placement Agent Warrants shall be delivered to the Placement Agent in accordance with Section 5 hereto.


 


(j)
All proceedings taken at or prior to any Closing in connection with the authorization, issuance and sale of the Debentures and Warrants
will be reasonably satisfactory in form and substance to the Placement Agent and its counsel, and such counsel shall have been furnished
with all such documents, certificates and opinions as it may reasonably request upon reasonable prior notice in connection with the transactions
contemplated hereby.


 


7.
Conditions of Company’s Obligations. The obligations of the Company hereunder to effect a Closing are subject to the fulfillment,
at or before each Closing, of the following additional conditions or subject to the waiver of such condition or conditions by the Company:


 


(a)
Each of the representations and warranties made by the Placement Agent shall be true and correct at all times prior to and on each Closing
date.


 






    	8



    	Theralink Technologies, Inc.
	November
                                            29, 2022




    

 


(b)
The Placement Agent shall have performed and complied in all material respects with all agreements, covenants and conditions required
to be performed and complied with by it at or before the Closing; and


 


(c)
The Company shall have received a certificate of an officer of the Placement Agent, dated as of the date of each Closing, certifying,
as to the fulfillment of the conditions set forth in subparagraphs (a) and (b) above; and


 


(d)
No order suspending the use of the Disclosure Materials or enjoining the Offering shall have been issued, and no proceedings for that
purpose or a similar purpose shall have been initiated or pending, or, to the Company’s knowledge, be contemplated or threatened.


 


8.Indemnification.
(a)The Company will: (i) indemnify and hold harmless the Placement Agent, its agents and their respective officers, directors, employees,
selected dealers and each person, if any, who controls the Placement Agent within the meaning of the Section 15 of the Act or Section
20(a) of the Exchange Act and such selected dealers (each an “Indemnitee” or a “Placement Agent Party”)
against, and pay or reimburse each Indemnitee for, any and all losses, claims, damages, liabilities or expenses whatsoever (or actions
or proceedings or investigations in respect thereof), joint or several (which will, for all purposes of this Agreement, include, but
not be limited to, all reasonable costs of defense and investigation and all reasonable attorneys’ fees, including appeals), to
which any Indemnitee may become subject (x) under the Act or otherwise, in connection with the offer and sale of the Debentures and Warrants
and (y) as a result of the breach of any representation, warranty or covenant made by the Company, regardless of whether such losses,
claims, damages, liabilities or expenses shall result from any claim by any Indemnitee or by any third party; and (ii) reimburse each
Indemnitee for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim,
action, proceeding or investigation; provided, however, that the Company will not be liable in any such case
to the extent that any such claim, damage or liability is finally judicially determined to have resulted primarily from (A) an untrue
statement or alleged untrue statement of a material fact made in the Disclosure Materials, or an omission or alleged omission to state
therein a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading,
made solely in reliance upon and in conformity with written information furnished to the Company by the Placement Agent specifically
for use in the Disclosure Materials, (B) any violations by the Placement Agent of the Act, state securities laws or any rules or regulations
of FINRA, which is not directly caused from a violation thereof by the Company or any of its affiliates or (C) the Placement Agent’s
willful misconduct or gross negligence. In addition to the foregoing agreement to indemnify and reimburse, the Company will indemnify
and hold harmless each Indemnitee against any and all losses, claims, damages, liabilities or expenses whatsoever (or actions or proceedings
or investigations in respect thereof), joint or several (which shall, for all purposes of this Agreement, include, but not be limited
to, all reasonable costs of defense and investigation and all reasonable attorneys’ fees, including appeals) to which any Indemnitee
may become subject insofar as such costs, expenses, losses, claims, damages or liabilities arise out of or are based upon the claim of
any person or entity that he or it is entitled to broker’s or finder’s fees from any Indemnitee in connection with the Offering,
other than fees due to the Placement Agent. The foregoing indemnity agreements will be in addition to any liability the Company may otherwise
have.


 






    	9



    	Theralink Technologies, Inc.
	November
                                            29, 2022




    

 


(b)
The Placement Agent will indemnify and hold harmless the Company, its officers, directors, and each person, if any, who controls such
entity within the meaning of Section 15 of the Act or Section 20(a) of the Exchange Act against, and pay or reimburse any such person
for, any and all losses, claims, damages, liabilities or expenses whatsoever (or actions, proceedings or investigations in respect thereof)
to which the Company or any such person may become subject under the Act or otherwise, whether such losses, claims, damages, liabilities
or expenses shall result from any claim of the Company or any such person who controls the Company within the meaning of the Act or by
any third party, but only to the extent that such losses, claims, damages or liabilities results from (i) an untrue statement or alleged
untrue statement of a material fact made in the Disclosure Materials, or an omission or alleged omission to state therein a material
fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, made in
reliance upon and in conformity with written information furnished to the Company by the Placement Agent, specifically for use in the
Disclosure Materials, (ii) as a result of the breach of any representation, warranty or covenant made by the Placement Agent, regardless
of whether such losses, claims, damages, liabilities or expenses shall result from any claim by any third party, or (iii) any violations
by the Placement Agent of the Act or state securities laws which does not result from a violation thereof by the Company or any of its
affiliates. The Placement Agent will reimburse the Company or any such person for any legal or other expenses reasonably incurred in
connection with investigating or defending against any such loss, claim, damage, liability or action, proceeding or investigation to
which such indemnity obligation applies. The foregoing indemnity agreements are in addition to any liability which the Placement Agent
may otherwise have. Notwithstanding the foregoing, in no event shall Placement Agent’s indemnification obligation hereunder exceed
the amount of Placement Agent’s Cash Fees actually received by the Placement Agent hereunder.


 


(c)
Promptly after receipt by an indemnified party under this Section 8 of notice of the commencement of any action, claim, proceeding or
investigation (the “Action”), such indemnified party, if a claim in respect thereof is to be made against the indemnifying
party under this Section 8, will notify the indemnifying party of the commencement thereof, but the omission to so notify the indemnifying
party will not relieve it from any liability that it may have to any indemnified party under this Section 8 unless the indemnifying party
has been substantially prejudiced by such omission. The indemnifying party will be entitled to participate in and, to the extent that
it may wish, jointly with any other indemnifying party, to assume the defense thereof subject to the provisions herein stated, with counsel
reasonably satisfactory to such indemnified party. The indemnified party will have the right to employ separate counsel in any such Action
and to participate in the defense thereof, but the fees and expenses of such counsel will not be at the expense of the indemnifying party
if the indemnifying party has assumed the defense of the Action with counsel reasonably satisfactory to the indemnified party, provided,
however, that if counsel selected to represent the indemnified party shall have concluded that there may be a conflict
of interest which prevents it from representing the indemnified party and the indemnifying party, then the indemnified party may retain
additional counsel to represent it and in such case the reasonable fees and expenses of such counsel in connection with any such participation
or defenses shall be paid by the indemnifying party. No settlement of any Action against an indemnified party will be made without the
consent of the indemnifying party and the indemnified party, which consent shall not be unreasonably withheld, delayed or conditioned
in light of all factors of importance to such party, and no indemnifying party shall be liable to indemnify any person for any settlement
of any such claim effected without such indemnifying party’s consent.


 






    	10



    	Theralink Technologies, Inc.
	November
                                            29, 2022




    

 


9.
Contribution. To provide for just and equitable contribution, if: (i) an indemnified party makes a claim for indemnification pursuant
to Section 8 hereof and it is finally determined, by a judgment, order or decree not subject to further appeal that such claims for indemnification
may not be enforced, even though this Agreement expressly provides for indemnification in such case; or (ii) any indemnified or indemnifying
party seeks contribution under the Act, the Exchange Act, or otherwise, then each indemnifying party shall contribute to such amount
paid or payable by such indemnified party in such proportion as is appropriate to reflect not only such relative benefits but also the
relative fault of the Company on the one hand and the Placement Agent on the other in connection with the statements or omissions which
resulted in such losses, claims, damages, liabilities or expenses (or actions in respect thereof), as well as any other relevant equitable
considerations. The relative benefits received by the Company on the one hand and the Placement Agent on the other shall be deemed to
be in the same proportion as the total net proceeds from the Offering (before deducting expenses) received by the Company bear to the
total Placement Agent’s Cash Fees received by the Placement Agent. The relative fault, in the case of an untrue statement, alleged
untrue statement, omission or alleged omission will be determined by, among other things, whether such statement, alleged statement,
omission or alleged omission relates to information supplied by the Company or by the Placement Agent, and the parties’ relative
intent, knowledge, access to information and opportunity to correct or prevent such statement, alleged statement, omission or alleged
omission. The Company and the Placement Agent agree that it would be unjust and inequitable if the respective obligations of the Company
and the Placement Agent for contribution were determined by pro rata allocation of the aggregate losses, liabilities, claims, damages
and expenses or by any other method or allocation that does not reflect the equitable considerations referred to in this Section 9. No
person guilty of a fraudulent misrepresentation (within the meaning of Section 10(f) of the Act) will be entitled to contribution from
any person who is not guilty of such fraudulent misrepresentation. For purposes of this Section 9, each person, if any, who controls
the Placement Agent within the meaning of the Act will have the same rights to contribution as the Placement Agent, and each person,
if any, who controls the Company within the meaning of the Act will have the same rights to contribution as the Company, subject in each
case to the provisions of this Section 9. Anything in this Section 9 to the contrary notwithstanding, no party will be liable for contribution
with respect to the settlement of any claim or action effected without its written consent. This Section 9 is intended to supersede,
to the extent permitted by law, any right to contribution under the Act, the Exchange Act or otherwise available.


 


10.
Miscellaneous.


 


(a)
Survival. Any termination of the Offering without consummation thereof shall be without obligation on the part of any party except
the Company’s payment of fees and expenses pursuant to Sections 3(g), 5(a) and 5(b) hereof, the indemnification provisions provided
in Section 8 hereof, the contribution provided in Section 9 hereof shall survive any termination. In addition, the provisions contained
in Section 8 regarding indemnification and Section 9 regarding contribution shall survive the Final Closing.


 






    	11



    	Theralink Technologies, Inc.
	November
                                            29, 2022




    

 


(b)
Representations, Warranties and Covenants to Survive Delivery. The respective representations, warranties, indemnities, agreements,
covenants and other statements of the Company as of the date hereof shall survive execution of this Agreement and delivery of the Debentures
and Warrants and the termination of this Agreement for a period of eighteen months.


 


(c)
No Other Beneficiaries. This Agreement is intended for the sole and exclusive benefit of the parties hereto and their respective
successors and controlling persons, and no other person, firm or corporation shall have any third-party beneficiary or other rights hereunder.
This Agreement may not be assigned without the prior written consent of the parties hereto.


 


(d)
Governing Law. This Agreement shall be governed by and construed under the laws of the State of New York as applied to agreements among
New York residents entered into and to be performed entirely within New York. Each of the parties hereto (1) agree that any legal suit,
action or proceeding arising out of or relating to this Agreement shall be instituted exclusively in New York State Supreme Court, County
of New York, or in the United States District Court for the Southern District of New York, (2) waive any objection which the Company
may have now or hereafter to the venue of any such suit, action or proceeding, and (3) irrevocably consent to the jurisdiction of the
New York State Supreme Court, County of New York, and the United States District Court for the Southern District of New York in any such
suit, action or proceeding. Each of the parties hereto further agrees to accept and acknowledge service of any and all process which
may be served in any such suit, action or proceeding in the New York State Supreme Court, County of New York, or in the United States
District Court for the Southern District of New York and agree that service of process upon it mailed by certified mail to its address
set forth in Section 10(f) below shall be deemed in every respect effective service of process upon it, in any such suit, action or proceeding.
THE PARTIES HERETO AGREE TO WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF
THIS AGREEMENT OR ANY DOCUMENT OR AGREEMENT CONTEMPLATED HEREBY.


 


(e)
Counterparts. This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts,
each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement and shall
become effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties
hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall constitute valid and sufficient
delivery thereof.


 






    	12



    	Theralink Technologies, Inc.
	November
                                            29, 2022




    

 


(f)
Notices. All notices, requests, demands and other communications which are required or may be given hereunder shall be in writing
and shall be deemed to have been duly given when delivered personally or by email or five (5) days after being sent by registered or
certified mail, return receipt requested, postage prepaid. All notices shall be made to the parties at the addresses designated above
or at such other or different addresses which a party may subsequently provide with notice thereof, and to their respective legal counsel,
as follows:


 


(i).
If to Gunnar, to:


 


Joseph
Gunnar & Co., LLC

30 Broad Street, 11th floor

New York, NY 10004

Attention: Stephan A Stein, President

Email: SStein@jgunnar.com


 


with
a copy to:


 


Olshan
Frome Wolosky LLP


1325
Avenue of the Americas


New
York, NY 10019

Attention: Kenneth A. Schlesinger, Esq.

Email: KSchlesinger@olshanlaw.com


 


or
to such other person or address as Gunnar shall furnish to the Company in writing.


 


(ii)
If to the Company, to:


 


Theralink
Technologies, Inc.

15000 W. 6th Ave., #400


Golden,
CO 80401

Attn: Mick Ruxin, M.D.

Email: mick.ruxin@theralink.com



 


with
a copy to:


 


K&L
Gates LLP


Southeast
Financial Center


200
S. Biscayne Boulevard, Suite 3900


Miami,
FL 33131

Attn: Erin Fogarty, Esq.; Clayton Parker, Esq.

Email: erin.fogarty@klgates.com; clayton.Parker@klgates.com


 


or
to such other person or address as the Company shall furnish to Gunnar in writing.


 


(g)
Entire Agreement. This Agreement constitutes the entire agreement of the parties with respect to the matters herein referred and
this Agreement has no bearing or effect on any prior agreements entered into by the parties hereto. Neither this Agreement nor any term
hereof may be changed, waived or terminated orally, but only by an instrument in writing signed by the party against which enforcement
of the change, waiver or termination is sought.


 


(h)
No Commitment. The execution of this Agreement does not constitute a commitment by Gunnar or the Company to consummate any transaction
contemplated hereunder and there can be no assurance that Gunnar will be able to locate any third parties to provide financing to the
Company.


 


[SIGNATURE
PAGE FOLLOWS]


 






    	13



    	 



    

 


If
the foregoing accurately reflects our understanding, please so indicate by signing in the space provided below.


 


	 	Sincerely,
	 	 
	 	JOSEPH
    GUNNAR & CO., LLC.
	 	 
	 	By:	/s/
    Stephan A. Stein
	 	Name:	Stephan
    A. Stein
	 	Title:	President



 


	Agreed
                                            to and Accepted

                                                                     this
                                            29th day of November, 2022
	 
	 	 
	THERALINK
    TECHNOLOGIES, INC.	 
	 	 
	By:	/s/
    Mick Ruxin	 
	Name:	Mick
    Ruxin, M.D.	 
	Title:	Chief
    Executive Officer	 





 


[Signature
Page to Placement Agent Agreement]